Metformin may reduce oral cancer risk in patients with type 2 diabetes.

ABSTRACT:

Background

Whether metformin use may affect the risk of oral cancer required further investigation.

Methods

The reimbursement database of the National Health Insurance in Taiwan was used. Patients with type 2 diabetes mellitus at an onset age of 25-74 years during 1999-2005 and newly treated with either metformin (n = 288198, "ever users of metformin") or other antidiabetic drugs (n = 16263, "never users of metformin") were followed for at least 6 months for oral cancer until December 31, 2011. The treatment effect of metformin (for ever versus never users, and for tertiles of cumulative duration of therapy) was estimated by Cox regression adjusted for propensity score (PS) or incorporated with the inverse probability of treatment weighting (IPTW) using PS.

Results

Th

SUBMITTER: Tseng CH 

PROVIDER: S-EPMC4811512 | biostudies-literature | 2016 Jan

REPOSITORIES: biostudies-literature